Press release

22.03.2023 To the attention of interested persons Synapse Labs Pvt. Ltd: re-examination confirms suspension of medicines over flawed studies download […]

Press release

12.03.2024 To the attention of interested persons Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-7 March 2024 download […]

Press release

12.01.2024 To the attention of interested persons Potential risk of neurodevelopmental disorders in children born to men treated with valproate […]

Press release

12.12.2023 To the attention of interested persons First version of the Union list of critical medicines agreed to help avoid […]

Press release

12.12.2023 To the attention of interested persons Questions and answers on the Union list of critical medicines download document …

Press release

01.12.2023 To the attention of interested persons Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 November 2023 download […]

Important notification

01.11.2023 To the attention of marketing authorization holders Regarding Direct healthcare professional communications, we want to inform you of the […]

Press release

31.10.2023 To the attention of interested persons EMA recommends approval of adapted Nuvaxovid COVID-19 vaccine targeting Omicron XBB.1.5 download document […]

Press release

18.10.2023 To the attention of interested persons EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens […]

Press release

06.10.2023 To the attention of interested persons Revised transparency rules for the EU Clinical Trials Information System (CTIS) download document […]